10,659 Shares in Arcellx, Inc. (NASDAQ:ACLX) Purchased by Walleye Capital LLC

Walleye Capital LLC acquired a new stake in Arcellx, Inc. (NASDAQ:ACLX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 10,659 shares of the company's stock, valued at approximately $817,000.

A number of other hedge funds have also recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Arcellx by 9.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,836 shares of the company's stock valued at $754,000 after purchasing an additional 858 shares in the last quarter. Lord Abbett & CO. LLC increased its position in shares of Arcellx by 2.1% during the third quarter. Lord Abbett & CO. LLC now owns 891,848 shares of the company's stock valued at $74,478,000 after acquiring an additional 18,004 shares during the last quarter. Swiss National Bank boosted its position in Arcellx by 0.8% in the fourth quarter. Swiss National Bank now owns 63,400 shares of the company's stock worth $4,862,000 after purchasing an additional 500 shares during the last quarter. Avanza Fonder AB bought a new position in Arcellx during the fourth quarter valued at about $184,000. Finally, Rhumbline Advisers lifted its stake in Arcellx by 1.9% in the fourth quarter. Rhumbline Advisers now owns 59,903 shares of the company's stock valued at $4,594,000 after purchasing an additional 1,125 shares during the last quarter. 96.03% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Arcellx

In other news, insider Rami Elghandour sold 38,300 shares of Arcellx stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $62.02, for a total value of $2,375,366.00. Following the transaction, the insider now owns 149,186 shares in the company, valued at approximately $9,252,515.72. The trade was a 20.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Christopher Heery sold 10,155 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $63.79, for a total value of $647,787.45. Following the sale, the insider now owns 37,486 shares of the company's stock, valued at $2,391,231.94. This represents a 21.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 54,455 shares of company stock worth $3,408,458 over the last 90 days. Corporate insiders own 6.24% of the company's stock.

Arcellx Stock Performance

Arcellx stock traded down $0.26 during mid-day trading on Friday, reaching $63.71. The company's stock had a trading volume of 295,950 shares, compared to its average volume of 556,205. The company has a market capitalization of $3.51 billion, a P/E ratio of -89.73 and a beta of 0.33. The firm's fifty day moving average price is $64.76 and its two-hundred day moving average price is $74.65. Arcellx, Inc. has a 12-month low of $47.88 and a 12-month high of $107.37.

Arcellx (NASDAQ:ACLX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.24). Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. The company had revenue of $15.27 million for the quarter, compared to analysts' expectations of $27.42 million. On average, research analysts predict that Arcellx, Inc. will post -1.58 EPS for the current fiscal year.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).